Atrial fibrillation (AF) continues to be a leading cause of cerebrovascular morbidity and
mortality resulting from cardioembolic stroke. Oral anticoagulation therapy has been shown …

Atrial fibrillation (AF), a common arrhythmia, increases the risk of ischemic stroke. Stroke and
bleeding scores for patients with AF can help to stratify risk and determine the need for …

Anticoagulation for the prevention of stroke is an important aspect of the management of
atrial fibrillation. Novel anticoagulants including oral factor Xa inhibitors rivaroxaban and …

Novel oral anticoagulants, including dabigatran, rivaroxaban, and apixaban, represent new
options for preventing stroke in patients with atrial fibrillation, as shown by the results from …

Atrial fibrillation is the most frequent arrhythmia in clinical practice, reaching 2% of the
people in the world and is associated with systemic embolism. Thus, the use of …

Atrial fibrillation (AF) is the most commonly occurring arrhythmia, and is a condition of both
significant clinical and economic importance. An antithrombotic agent is considered …

BACKGROUND: Warfarin had been the only oral anticoagulant for stroke prevention in
patients with atrial fibrillation (AF) for decades. Direct thrombin inhibitors and factor Xa …

The presence of atrial fibrillation (AF), the most common sustained cardiac arrhythmia,
significantly increases the risk for stroke. Current guidelines recommend that the vitamin K …

New oral anticoagulants, including apixaban, dabigatran, and rivaroxaban, have been
developed as alternatives to warfarin, the standard oral anticoagulation therapy for patients …

Atrial fibrillation (AF) is the most common cardiac rhythm disorder and a major risk factor for
ischemic stroke. Antithrombotic therapy using aspirin or vitamin K antagonists (VKA) is …